Recombinant Virus Vaccines
Document text
Principal Investigator: Bernard Moss Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES Fiscal Year: 2023 Award: $1,717,946 Funding agency: National Institute of Allergy and Infectious Diseases During F7'23 progress has been made in developing an improved vaccine for mpox and infections caused by other orthopoxviruses. One approach carried in collaboration with the company Moderna uses mRNAs expressing four modified mpox virus proteins encapsulated in a lipid particle. We have shown that the single mRNAs are immunogenic and provide partial protection and multiple mRNAs provide complete protection against vaccinia virus in mouse models. In a second approach we have made protein nanoparticles containing multiple copies of truncated mpox virus proteins and showed that they also completely protect against vaccinia virus infection in a mouse model. Terms: <Animal Model><Animal Models and Related Studies><Cell Mediated Immunology><Cell-Mediated Immunity><Cellular Immunity><Collaborations><Disease><Disorder><Encapsulated><Infection><Lipids><Messenger RNA><Monkey Pox><Monkeypox><Orthopox virus><Orthopoxvirus><Poxvirus officinale><Proteins><RNA vaccine><RNA-based vaccine><Recombinant Proteins><Recombinant Viral Vaccine><Research><Testing><Vaccines><Vaccinia virus><Viral Antigens><Viral Diseases><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Virus Diseases><immunogenic><improved><mRNA><mRNA vaccine><mRNA-based vaccine><model of animal><mouse model><mpox><murine model><nano particle><nano-sized particle><nanoparticle><nanosized particle><particle><recombinant vaccinia virus><recombinant virus vaccine><side effect><vaccine candidate><vector><viral infection><virus antigen><virus infection><virus protein><virus-induced disease>